Oral semaglutide trial shows fewer heavy drinking days, pointing to a potential new indication for Alcohol Use Disorder
Executive summary: A clinical trial led by CU Anschutz researchers found that oral semaglutide reduced heavy drinking days in adults with Alcohol Use Disorder. The result suggests a possible new indication for a blockbuster drug, which could expand its market and influence alcohol treatment approaches.
Who is involved: Researchers at the University of Colorado Anschutz, adults diagnosed with Alcohol Use Disorder, and the investigational drug oral semaglutide (marketed by Novo Nordisk as Rybelsus).
Likely next: Study authors may pursue regulatory submission for an AUD indication; the sponsor could prepare a supplemental New Drug Application for FDA review.
A University of Colorado Anschutz clinical trial reported that participants taking oral semaglutide experienced a reduction in heavy drinking days compared to placebo. The findings add to growing evidence that GLP-1 receptor agonists may affect reward pathways linked to alcohol consumption. If corroborated, the data could support a supplemental label expansion for the drug, broadening its therapeutic use beyond diabetes and obesity.
Timeline
- — Can Oral Semaglutide Reduce Alcohol Use? CU Anschutz Clinical Trial Shows Fewer Heavy Drinking Days (PR Newswire)
Analysis — what this means
Likely next events
- Company may submit a supplemental New Drug Application (sNDA) to the FDA for oral semaglutide in AUD by Q4 2026
- Full trial data expected to be presented at the American Diabetes Association Scientific Sessions in June 2027
- Payers may begin reviewing coverage policies for oral semaglutide in AUD during 2027 formulary cycles
Sectors affected
- Pharmaceuticals – GLP-1 receptor agonist manufacturers
- Alcohol use disorder treatment services
- Health insurance/payers (formulary decision-making)
Regulatory implications
- Will require a supplemental New Drug Application (sNDA) to the FDA for an AUD indication, triggering a standard 10‑month review cycle
- Post‑marketing safety studies may be mandated under FDA’s 21 CFR 314.81 to monitor long‑term use in AUD populations
Historical parallels
- FDA approval of semaglutide (Wegovy) for chronic weight management in June 2021
- Approval of naltrexone (ReVia) for alcohol dependence in 1994
- Repurposing of bupropion (Zyban) for smoking cessation, approved 1997
Sources
- Can Oral Semaglutide Reduce Alcohol Use? CU Anschutz Clinical Trial Shows Fewer Heavy Drinking Days — PR Newswire
Related cases
- Menu-Order AI appoints medical advisor to strengthen clinical credibility for its GLP-1-focused dietary AI platform
- GLP-1 weight-loss drugs face scrutiny over reported side‑effects like ‘Ozempic face’ and hair loss
- Cathie Wood’s Ark Invest is increasing its stake in a GLP-1 pharmaceutical stock that has appreciated 1,600% over the last decade
- The focus on GLP-1 stocks indicates changing market sentiment beyond traditional drug manufacturers
- The rising demand for high-protein whey amidst a significant shortage highlights critical shifts in the wellness industry
- Increased adoption of weight-loss drugs leads to substantial savings on grocery expenses for households